Genomic Health, Inc.: Still Waiting for Reimbursement

Genomic Health, Inc.: Still Waiting for Reimbursement

Genomic Health's (NASDAQ: GHDX) revenue continues to grow slowly because of a delay in Medicare reimbursement for its prostate cancer test, but the genomic test maker was still able to reduce its net loss, moving the company closer to its goal of being profitable for the entire year.

Metric

Q2 2017

Continue reading

Source: Fool.com